EnliTlSA: a Clinical-Stage Biotech with revenue focusing on inflammation
EnliTISA is a multi-drug development company and the vision is to develop more effective, safer and better tolerated anti-inflammatory and anti-fibrosis drugs.
- EnliTISA is a multi-drug development company and the vision is to develop more effective, safer and better tolerated anti-inflammatory and anti-fibrosis drugs. 16 patent applications have been filed. Three patents have been granted respectively in China, in US and in several other territories.
- Now, EnliTISA is a clinical stage drug development company. The phase II clinical trial on acute respiratory distress syndrome (ARDS) has been completed in China, in March 2025; the phase Ib clinical trial on radiation-induced oral mucositis is in progress in China; and the phase I study in IPF by subcutaneous injection was completed in Sweden, in December 2024. In the future, EnliTISA could be developed into a full scale pharmaceutical company in China according to the plan of the founders.
- The main business model in early stage focuses on out-licensing. In 2021 and 2022, EnliTISA signed license agreement with a leading big pharma in China, Shanghai Pharma. Our out-licensing business model is proven successful through ongoing partnerships, including collaborations with Shanghai Pharma that have generated revenue from 2021 through 2024.
- EnliTISA won the silver medal of the 13th China Innovation & Entrepreneurship Competition in 2024, which was a national competition and organized by the Torch High Technology Industry Development Center, Ministry of Industry and Information Technology of China.
Founded in
International invention patents
- Active Partnerships & Revenue Generation Since 2021
Organizational
Our team
Now, EnliTISA is a clinical stage drug development company. The phase II clinical trial on acute respiratory distress syndrome (ARDS) has been completed in China, in March 2025; the phase Ib clinical trial on radiation-induced oral mucositis is in progress in China; and the phase I study in IPF by subcutaneous injection was completed in Sweden, in December 2024. In the future, EnliTISA could be developed into a full scale pharmaceutical company in China according to the plan of the founders.
The main business model in early stage focuses on out-licensing. In 2021 and 2022, EnliTISA signed license agreement with a leading big pharma in China, Shanghai Pharma. Our out-licensing business model is proven successful through ongoing partnerships, including collaborations with Shanghai Pharma that have generated revenue from 2021 through 2024.
EnliTISA won the silver medal of the 13th China Innovation & Entrepreneurship Competition in 2024, which was a national competition and organized by the Torch High Technology Industry Development Center, Ministry of Industry and Information Technology of China.
FUNDERS Of EnliTISA
Prof. Bengt Samuelsson
Laureate of the Nobel Prize in Physiology or Medicine
Prof. Jan-Christer Janson
Protein and Peptide Purification and Modification Scientist
Prof. Jesper Haeggstrom
Focus on basic research on inflammation, including research on new targets
Prof. Gu Ming , Founder , CEO
Expert in Protein and Peptide Basic Research Experienced entrepreneur
OPERATION TEAM
Dr. Jiang Taotao, CMC
Fudan University, Ph.D. in Pharmaceutics; Over 20 years of experience in pharmaceutical research in the biopharmaceutical field
Dr. Kang Ruijuan, Preclinical
Ph.D. in Biochemical Engineering; Experienced in pre-clinical study
Prof. Gu Ming , Founder , CEO
Expert in Protein and Peptide Basic Research Experienced entrepreneur
Ru Hui, COO
15 years experience as CFO and Executive Vice President Responsible for the overall operation of the company
MEDICAL TEAM
Dr. Anders Kärnell，CMO
Specialist in Infectious Diseases Former Chief Medical Officer at Merck Sharp & Dohme (MSD) Sweden
Jiao Feifei
China Pharmaceutical University, Pharmacy (human pharmacokinetics)
Su Lingling
Clinical Medicine, Chao Yang Hospital Capital Medical University 14 years physician in respiratory and critical care medicine
CONSULTANTS ON CLINICAL TRIAL APPLICATION & OPERATION IN EUROPE
Culture
Enlitisa
Honor
2024 Shanghai Top 50 Most Investment-Promising Startups
Top 50 Innovation & Entrepreneurship Enterprises list of the China Innovation & Entrepreneurship Competition
Second Prize in the Bio-medicine National Competition of the 13th China Innovation & Entrepreneurship Grand Prix
National High-tech Enterprise
Tel:+86-021-33758853
Add:Room 201, 202, 203, BuildingA, Block1, No. 800, Qingdai Road, Pudong New District, Shanghai
Contact：Dr. Gu Ming
E-mail： bdservice@tisatide.com
Copyright ©2022 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. | SEO 沪ICP备2022023966号-1 Powered by www.300.cn